What the FDA labels say about taking them together
Apalutamide and ensitrelvir
Ensitrelvir's FDA label of June 3, 2026 names apalutamide in its drug interactions section; the apalutamide label PlainMeds reads does not name ensitrelvir. The ensitrelvir label: “Co-administration is contraindicated due to potential loss of virologic response.”
Check it at the source: the apalutamide FDA label on DailyMed (effective July 2, 2026, Janssen Products, LP); the ensitrelvir FDA label on DailyMed (effective June 3, 2026, Shionogi Inc.).
What does the apalutamide label say about ensitrelvir?
Apalutamide's label (effective July 2, 2026) does not name ensitrelvir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ERLEADA), Janssen Products, LP, effective July 2, 2026 (SPL set d1cda4f7-cb33-46ea-b9ac-431f6452b1a5), via openFDA; the full label on DailyMed
What does the ensitrelvir label say about apalutamide?
Ensitrelvir label, drug interactionsDrug Class: Anticancer drugs; Drug (s) within Class: apalutamide, enzalutamide; Effect on Drug Concentration: ↓ ensitrelvir; Clinical Comment: Co-administration is contraindicated due to potential loss of virologic response.
Source: FDA drug label (XOCOVA), Shionogi Inc., effective June 3, 2026 (SPL set 526acf60-abc3-2cc2-e063-6294a90affa6), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Apalutamide | Ensitrelvir | |
|---|---|---|
| Labeled for | Prostate cancer | COVID-19 |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once